Overview

Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior Therapy

Status:
Terminated
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess efficacy and tolerability of changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-free) from prior Xalacom® or Ganfort® fixed combination pharmacotherapy in patients with open-angle glaucoma or ocular hypertension with uncontrolled intraocular pressure (IOP).
Phase:
Phase 4
Details
Lead Sponsor:
Alcon Research
Treatments:
Maleic acid
Timolol
Travoprost